US5354844A
(en)
*
|
1989-03-16 |
1994-10-11 |
Boehringer Ingelheim International Gmbh |
Protein-polycation conjugates
|
US6830923B1
(en)
*
|
1989-03-16 |
2004-12-14 |
Boehringer Inglheim International Gmbh |
Genetics units for inhibiting the function of RNA
|
ATE157012T1
(de)
*
|
1989-11-03 |
1997-09-15 |
Univ Vanderbilt |
Verfahren zur in vivo-verabreichung von funktionsfähigen fremden genen
|
DK0506884T3
(da)
*
|
1989-12-21 |
1996-11-04 |
Whitehead Biomedical Inst |
Fremgangsmåde til afgivelse af molekyler til eukaryotiske celler
|
US5652122A
(en)
*
|
1989-12-21 |
1997-07-29 |
Frankel; Alan |
Nucleic acids encoding and methods of making tat-derived transport polypeptides
|
US6316003B1
(en)
|
1989-12-21 |
2001-11-13 |
Whitehead Institute For Biomedical Research |
Tat-derived transport polypeptides
|
US5804604A
(en)
*
|
1989-12-21 |
1998-09-08 |
Biogen, Inc. |
Tat-derived transport polypeptides and fusion proteins
|
DE59107006D1
(de)
*
|
1990-04-25 |
1996-01-18 |
Hoechst Ag |
Pharmakologische Zubereitung, enthaltend Polyelektrolytkomplexe in mikropartikulärer Form und mindestens einen Wirkstoff.
|
ES2078521T3
(es)
*
|
1990-05-18 |
1995-12-16 |
Boehringer Ingelheim Int |
Nuevos conjugados de proteina-polication.
|
DE4110410C2
(de)
*
|
1991-03-29 |
1999-05-27 |
Boehringer Ingelheim Int |
Neue Protein-Polykation-Konjugate
|
DE4104186A1
(de)
*
|
1991-02-12 |
1992-08-13 |
Genentech Inc |
Neue, ueber endozytose in hoehere eukaryotische zellen aufnehmbare, nukleinsaeure enthaltende komplexe
|
DE4110409C2
(de)
*
|
1991-03-29 |
1999-05-27 |
Boehringer Ingelheim Int |
Neue Protein-Polykation-Konjugate
|
DE4115038A1
(de)
*
|
1991-05-08 |
1992-11-12 |
Genentech Inc |
Neue konjugate, bestehend aus einem glykoprotein und einer nukleinsaeure-bindenden substanz
|
US6030954A
(en)
*
|
1991-09-05 |
2000-02-29 |
University Of Connecticut |
Targeted delivery of poly- or oligonucleotides to cells
|
US5981273A
(en)
*
|
1991-09-30 |
1999-11-09 |
Boehringer Ingelheim Int'l. Gmbh |
Composition comprising an endosomolytic agent for introducing nucleic acid complexes into higher eucaryotic cells
|
NZ244306A
(en)
*
|
1991-09-30 |
1995-07-26 |
Boehringer Ingelheim Int |
Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
|
US5521291A
(en)
*
|
1991-09-30 |
1996-05-28 |
Boehringer Ingelheim International, Gmbh |
Conjugates for introducing nucleic acid into higher eucaryotic cells
|
RU2138553C1
(ru)
*
|
1991-09-30 |
1999-09-27 |
Берингер Ингельгейм Интернациональ ГмбХ |
Трансфекционная композиция для высших эукариотных клеток, комплекс нуклеиновой кислоты, пригодный в качестве компонента трансфекционной композиции, конъюгат, пригодный в качестве компонента трансфекционной композиции, эндосомолитический пептид, пригодный в качестве компонента трансфекционной композиции
|
IL103059A0
(en)
*
|
1991-09-30 |
1993-02-21 |
Boehringer Ingelheim Int |
Conjugates for introducing nucleic acid into higher eucaryotic cells
|
DE4139001A1
(de)
*
|
1991-11-27 |
1993-06-03 |
Boehringer Mannheim Gmbh |
Verfahren zur einschleusung von nukleinsaeuren in zellen
|
JP3468518B2
(ja)
*
|
1991-12-23 |
2003-11-17 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ニューロブラストーマ関連調節遺伝子
|
US5922859A
(en)
*
|
1992-02-01 |
1999-07-13 |
Boehringer Ingelheim International Gmbh |
Complexes containing nucleic acid which can be taken-up by endocytosis into higher eukaryotic cells
|
EP0636028B1
(en)
*
|
1992-04-03 |
2004-03-03 |
The Regents Of The University Of California |
Self-assembling polynucleotide delivery system comprising an amphiphatic cationic peptide
|
US5656609A
(en)
*
|
1992-09-24 |
1997-08-12 |
University Of Connecticut |
Method of enhancing and/or prolonging expression of gene introduced into a cell using colchicine
|
DE4311651A1
(de)
*
|
1993-04-08 |
1994-10-13 |
Boehringer Ingelheim Int |
Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
|
WO1994023751A1
(de)
*
|
1993-04-14 |
1994-10-27 |
Boehringer Mannheim Gmbh |
Nukleinsäure-transferpeptide und deren verwendung zur einschleusung von nukleinsäuren in eukaryontische zellen
|
US6106824A
(en)
*
|
1993-08-13 |
2000-08-22 |
The Rockefeller University |
Expression of growth associated protein B-50/GAP-43 in vitro and in vivo
|
RU2025487C1
(ru)
*
|
1993-10-18 |
1994-12-30 |
Товарищество с ограниченной ответственностью "БиоПрогресс" |
Способ направленной генетической трансформации молочной железы животного и устройство для введения генетического материала в молочный проток молочной железы животного
|
US20030036056A1
(en)
*
|
1994-01-24 |
2003-02-20 |
John J. Rossi |
Inhibitors and target molecule co-localization
|
FR2715847B1
(fr)
*
|
1994-02-08 |
1996-04-12 |
Rhone Poulenc Rorer Sa |
Composition contenant des acides nucléiques, préparation et utilisations.
|
CA2183667A1
(en)
*
|
1994-02-22 |
1995-08-24 |
Wayne A. Marasco |
Nucleic acid delivery system, method of synthesis and uses thereof
|
US6037329A
(en)
*
|
1994-03-15 |
2000-03-14 |
Selective Genetics, Inc. |
Compositions containing nucleic acids and ligands for therapeutic treatment
|
US6551618B2
(en)
|
1994-03-15 |
2003-04-22 |
University Of Birmingham |
Compositions and methods for delivery of agents for neuronal regeneration and survival
|
US5844107A
(en)
*
|
1994-03-23 |
1998-12-01 |
Case Western Reserve University |
Compacted nucleic acids and their delivery to cells
|
US5972901A
(en)
|
1994-03-23 |
1999-10-26 |
Case Western Reserve University |
Serpin enzyme complex receptor--mediated gene transfer
|
ATE410518T1
(de)
*
|
1994-03-23 |
2008-10-15 |
Univ Ohio |
Kompaktnukleinsäure und ihre verabreichung in zellen
|
US6077835A
(en)
*
|
1994-03-23 |
2000-06-20 |
Case Western Reserve University |
Delivery of compacted nucleic acid to cells
|
US5670347A
(en)
*
|
1994-05-11 |
1997-09-23 |
Amba Biosciences Llc |
Peptide-mediated gene transfer
|
WO1995033062A2
(de)
|
1994-05-30 |
1995-12-07 |
Boehringer Ingelheim International Gmbh |
Verfahren zum einbringen von fremdmaterial in höhere eukaryotische zellen
|
DE4418965A1
(de)
*
|
1994-05-31 |
1995-12-07 |
Boehringer Ingelheim Int |
Verfahren zum Einbringen von Nukleinsäure in höhere eukaryotische Zellen
|
EP0769063A1
(en)
*
|
1994-06-27 |
1997-04-23 |
The Johns Hopkins University |
Targeted gene delivery system
|
US5728399A
(en)
*
|
1994-06-29 |
1998-03-17 |
University Of Conn. |
Use of a bacterial component to enhance targeted delivery of polynucleotides to cells
|
US6048837A
(en)
*
|
1994-08-17 |
2000-04-11 |
The Rockefeller University |
OB polypeptides as modulators of body weight
|
US6471956B1
(en)
|
1994-08-17 |
2002-10-29 |
The Rockefeller University |
Ob polypeptides, modified forms and compositions thereto
|
US6124448A
(en)
*
|
1994-08-17 |
2000-09-26 |
The Rockfeller University |
Nucleic acid primers and probes for the mammalian OB gene
|
US6350730B1
(en)
|
1994-08-17 |
2002-02-26 |
The Rockefeller University |
OB polypeptides and modified forms as modulators of body weight
|
US6309853B1
(en)
|
1994-08-17 |
2001-10-30 |
The Rockfeller University |
Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
|
US6001968A
(en)
|
1994-08-17 |
1999-12-14 |
The Rockefeller University |
OB polypeptides, modified forms and compositions
|
US6124439A
(en)
*
|
1994-08-17 |
2000-09-26 |
The Rockefeller University |
OB polypeptide antibodies and method of making
|
US6962686B2
(en)
|
1994-10-12 |
2005-11-08 |
California Institute Of Technology |
Cell-specific gene delivery vehicles
|
US6232295B1
(en)
|
1994-10-12 |
2001-05-15 |
Jon Faiz Kayyem |
Cell-specific contrast agent and gene delivery vehicles
|
GB9422495D0
(en)
*
|
1994-11-08 |
1995-01-04 |
Medical Res Council |
DNA transfer method
|
US6221959B1
(en)
|
1994-11-18 |
2001-04-24 |
Supratek Pharma, Inc. |
Polynucleotide compositions
|
AU4690596A
(en)
*
|
1994-12-30 |
1996-07-24 |
Chiron Viagene, Inc. |
Nucleic acid condensing agents with reduced immunogenicity
|
US5795587A
(en)
|
1995-01-23 |
1998-08-18 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
AU5259796A
(en)
|
1995-02-10 |
1996-08-27 |
Worcester Foundation For Biomedical Research, Inc. |
Delivery of exogenous compounds
|
FR2730637B1
(fr)
|
1995-02-17 |
1997-03-28 |
Rhone Poulenc Rorer Sa |
Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
|
US6420549B1
(en)
|
1995-06-06 |
2002-07-16 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide analogs having modified dimers
|
US5646034A
(en)
*
|
1995-06-07 |
1997-07-08 |
Mamounas; Michael |
Increasing rAAV titer
|
US6051429A
(en)
*
|
1995-06-07 |
2000-04-18 |
Life Technologies, Inc. |
Peptide-enhanced cationic lipid transfections
|
JP4338106B2
(ja)
*
|
1995-06-07 |
2009-10-07 |
ライフ テクノロジーズ コーポレーション |
ペプチド増強カチオン脂質トランスフェクション
|
US20030069173A1
(en)
*
|
1998-03-16 |
2003-04-10 |
Life Technologies, Inc. |
Peptide-enhanced transfections
|
US6127116A
(en)
*
|
1995-08-29 |
2000-10-03 |
Washington University |
Functional DNA clone for hepatitis C virus (HCV) and uses thereof
|
US5744326A
(en)
*
|
1996-03-11 |
1998-04-28 |
The Immune Response Corporation |
Use of viral CIS-acting post-transcriptional regulatory sequences to increase expression of intronless genes containing near-consensus splice sites
|
EP0904373A1
(en)
*
|
1996-03-14 |
1999-03-31 |
The Immune Response Corporation |
Targeted delivery of genes encoding interferon
|
US9096636B2
(en)
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US7812149B2
(en)
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
US5679559A
(en)
*
|
1996-07-03 |
1997-10-21 |
University Of Utah Research Foundation |
Cationic polymer and lipoprotein-containing system for gene delivery
|
CN1181422A
(zh)
*
|
1996-10-31 |
1998-05-13 |
上海市肿瘤研究所 |
与生长因子受体结合的多肽所构建的基因转移载体
|
US6387700B1
(en)
*
|
1996-11-04 |
2002-05-14 |
The Reagents Of The University Of Michigan |
Cationic peptides, Cys-Trp-(LYS)n, for gene delivery
|
US5965441A
(en)
*
|
1996-11-13 |
1999-10-12 |
The General Hospital Coporation |
HSV/AAV hybrid amplicon vectors
|
FR2755976B1
(fr)
|
1996-11-15 |
1999-01-15 |
Idm Immuno Designed Molecules |
Nouveaux complexes d'acides nucleiques et de polymere substitue par des residus entrainant la destabilisation des membranes cellulaires
|
US7008776B1
(en)
|
1996-12-06 |
2006-03-07 |
Aventis Pharmaceuticals Inc. |
Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
|
AU5729898A
(en)
*
|
1996-12-18 |
1998-07-15 |
Emory University |
Polycationic oligomers
|
US5969102A
(en)
|
1997-03-03 |
1999-10-19 |
St. Jude Children's Research Hospital |
Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
|
US7049428B1
(en)
|
1998-03-04 |
2006-05-23 |
Washington University |
HCV variants
|
US7338759B1
(en)
|
1997-03-04 |
2008-03-04 |
Washington University |
HCV variants
|
KR20010020342A
(ko)
|
1997-04-28 |
2001-03-15 |
자끄 사비나 |
종양치료용 맥관형성 길항제의 아데노바이러스-매개 종양내 전달방법
|
PL337033A1
(en)
|
1997-05-21 |
2000-07-31 |
Univ Leland Stanford Junior |
Composition for and methods of enhancing transport through permeable biological membranes
|
US6958148B1
(en)
|
1998-01-20 |
2005-10-25 |
Pericor Science, Inc. |
Linkage of agents to body tissue using microparticles and transglutaminase
|
US6919076B1
(en)
|
1998-01-20 |
2005-07-19 |
Pericor Science, Inc. |
Conjugates of agents and transglutaminase substrate linking molecules
|
AU2868099A
(en)
*
|
1998-02-13 |
1999-08-30 |
Selective Genetics, Inc. |
Concurrent flow mixing methods and apparatuses for the preparation of gene therapy vectors and compositions prepared thereby
|
US7101575B2
(en)
*
|
1998-03-19 |
2006-09-05 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Production of nanocapsules and microcapsules by layer-wise polyelectrolyte self-assembly
|
AU3758199A
(en)
*
|
1998-04-23 |
1999-11-08 |
Regents Of The University Of Michigan, The |
Peptides for efficient gene transfer
|
US6169078B1
(en)
*
|
1998-05-12 |
2001-01-02 |
University Of Florida |
Materials and methods for the intracellular delivery of substances
|
US6171855B1
(en)
|
1998-05-28 |
2001-01-09 |
The Regents Of The University Of Michigan |
Vectors
|
US6927278B1
(en)
*
|
1998-09-01 |
2005-08-09 |
Trustees Of The University Of Pennsylvania |
Peptide scaffolds for transfer of molecules into eukaryotic cells
|
US6696089B2
(en)
|
1998-09-03 |
2004-02-24 |
Board Of Regents Of The University Of Nebraska |
Nanogel networks including polyion polymer fragments and biological agent compositions thereof
|
US6077709A
(en)
|
1998-09-29 |
2000-06-20 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Survivin expression
|
WO2000027795A1
(en)
|
1998-11-12 |
2000-05-18 |
Invitrogen Corporation |
Transfection reagents
|
US6773911B1
(en)
|
1998-11-23 |
2004-08-10 |
Amgen Canada Inc. |
Apoptosis-inducing factor
|
US6395029B1
(en)
*
|
1999-01-19 |
2002-05-28 |
The Children's Hospital Of Philadelphia |
Sustained delivery of polyionic bioactive agents
|
US7098192B2
(en)
|
1999-04-08 |
2006-08-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of STAT3 expression
|
US6281005B1
(en)
|
1999-05-14 |
2001-08-28 |
Copernicus Therapeutics, Inc. |
Automated nucleic acid compaction device
|
US7674951B1
(en)
|
1999-05-21 |
2010-03-09 |
Michigan Technological University |
Isolated cellulose synthase promoter regions
|
US7049481B1
(en)
|
1999-05-21 |
2006-05-23 |
Board Of Control Of Michigan Technological University |
Cellulose synthase encoding polynucleotides and uses thereof
|
DE19929104A1
(de)
*
|
1999-06-24 |
2000-12-28 |
Aventis Pharma Gmbh |
Neue Vektorkomplexe und deren Verwendung für die Gentherapie
|
US6770740B1
(en)
|
1999-07-13 |
2004-08-03 |
The Regents Of The University Of Michigan |
Crosslinked DNA condensate compositions and gene delivery methods
|
DE19933506A1
(de)
*
|
1999-07-16 |
2001-01-25 |
Deutsches Krebsforsch |
Zelluläre Aufnahme von DNA
|
WO2001013723A1
(en)
*
|
1999-08-20 |
2001-03-01 |
Mirus Corporation |
Charge reversal of polyion complexes
|
US6669951B2
(en)
|
1999-08-24 |
2003-12-30 |
Cellgate, Inc. |
Compositions and methods for enhancing drug delivery across and into epithelial tissues
|
US6730293B1
(en)
|
1999-08-24 |
2004-05-04 |
Cellgate, Inc. |
Compositions and methods for treating inflammatory diseases of the skin
|
US7229961B2
(en)
|
1999-08-24 |
2007-06-12 |
Cellgate, Inc. |
Compositions and methods for enhancing drug delivery across and into ocular tissues
|
JP2003507438A
(ja)
|
1999-08-24 |
2003-02-25 |
セルゲイト, インコーポレイテッド |
オリゴアルギニン部分を使用する上皮組織を横切るおよび上皮組織内への薬物送達の増強
|
DE60031826T2
(de)
*
|
1999-12-08 |
2007-06-14 |
Jsr Corp. |
Trennung von Viren und Nachweis von Viren
|
AU2281201A
(en)
*
|
1999-12-29 |
2001-07-09 |
A. James Mixson |
Histidine copolymer and methods for using same
|
US7070807B2
(en)
*
|
1999-12-29 |
2006-07-04 |
Mixson A James |
Branched histidine copolymers and methods for using same
|
US6261840B1
(en)
|
2000-01-18 |
2001-07-17 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
US20020055479A1
(en)
|
2000-01-18 |
2002-05-09 |
Cowsert Lex M. |
Antisense modulation of PTP1B expression
|
US20030134420A1
(en)
*
|
2000-02-18 |
2003-07-17 |
Lollo Charles Peter |
Methods and compositions for gene delivery
|
ES2368419T3
(es)
|
2000-03-13 |
2011-11-17 |
Cornell Research Foundation, Inc. |
Bloqueo de la migración de leucocitos y de la inflamación por interferencia con cd99/hec2.
|
GB0018307D0
(en)
|
2000-07-26 |
2000-09-13 |
Aventis Pharm Prod Inc |
Polypeptides
|
EP2264072A1
(en)
|
2000-04-13 |
2010-12-22 |
The Rockefeller University |
Enhancement of antibody-mediated cytotoxicity.
|
WO2001082972A2
(en)
*
|
2000-04-23 |
2001-11-08 |
Arizeke Pharmaceuticals, Inc. |
Compositions comprising carriers and transportable complexes
|
EP1294770B1
(en)
|
2000-05-10 |
2011-12-07 |
Mayo Foundation For Medical Education And Research |
Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
|
US6680172B1
(en)
|
2000-05-16 |
2004-01-20 |
Regents Of The University Of Michigan |
Treatments and markers for cancers of the central nervous system
|
US7355019B2
(en)
|
2000-06-06 |
2008-04-08 |
Sibtech, Inc. |
Cysteine-containing peptide tag for site-specific conjugation of proteins
|
PT1320542E
(pt)
|
2000-08-08 |
2007-08-06 |
St Jude Childrens Res Hospital |
Ácidos nucleicos de estreptococo de grupo b, polipéptidos, composições terapêuticas e vacinas correspondentes
|
AU2001294890A1
(en)
*
|
2000-09-25 |
2002-04-02 |
Board Of Regents, The University Of Texas System |
Pei: dna vector formulations for in vitro and in vivo gene delivery
|
US20030166160A1
(en)
*
|
2001-09-06 |
2003-09-04 |
Hawley Stephen B. |
Compounds and molecular complexes comprising multiple binding regions directed to transcytotic ligands
|
JP2005500002A
(ja)
*
|
2000-10-02 |
2005-01-06 |
エリゼク・ファーマシュウティカルズ・インコーポレイテッド |
生物学的に活性な薬剤を細胞関門を越えて輸送するための組成物および方法
|
US8105825B2
(en)
|
2000-10-03 |
2012-01-31 |
Intrexon Corporation |
Multiple inducible gene regulation system
|
DE10049010A1
(de)
*
|
2000-10-04 |
2002-04-18 |
Boehringer Ingelheim Int |
Transferrin-Polykation/DNS-Komplexe für die systemische Therapie von Tumorerkrankungen mit zytotoxischen Proteinen
|
ES2359625T3
(es)
|
2000-12-28 |
2011-05-25 |
Wyeth Llc |
Proteina protectora recombinante de.
|
WO2002066612A2
(en)
|
2001-02-20 |
2002-08-29 |
Rheogene, Inc. |
Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
|
EP1572862B1
(en)
|
2001-02-20 |
2012-08-01 |
Intrexon Corporation |
Chimeric retinoid x receptors and their use in a novel ecdysone receptor-based inducible gene expression system
|
DK1499349T3
(da)
|
2001-03-02 |
2010-04-06 |
Univ Rockefeller |
Rekombinante hybrid-allergenkonstrukter med reduceret allergenitet, der bibeholder det naterulige allergens immunogenitet
|
EP1383492A4
(en)
*
|
2001-03-23 |
2008-12-24 |
Napro Biotherapeutics Inc |
MOLECULAR CONJUGATES FOR USE IN CANCER THERAPY
|
US20030096748A1
(en)
*
|
2001-06-04 |
2003-05-22 |
The Regents Of The University Of Michigan |
Methods and compositions for the treatment of diseases associated with signal transduction aberrations
|
US7803915B2
(en)
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
PT2000545E
(pt)
|
2001-06-20 |
2011-12-21 |
Genentech Inc |
Composições e métodos para o diagnóstico e tratamento do tumor pulmonar
|
EP2270024B1
(en)
|
2001-06-21 |
2018-10-24 |
Ionis Pharmaceuticals, Inc. |
Antisense modulation of superoxide dismutase 1, soluble expression
|
US7425545B2
(en)
|
2001-07-25 |
2008-09-16 |
Isis Pharmaceuticals, Inc. |
Modulation of C-reactive protein expression
|
US6964950B2
(en)
|
2001-07-25 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of C-reactive protein expression
|
US20030096772A1
(en)
|
2001-07-30 |
2003-05-22 |
Crooke Rosanne M. |
Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
|
US7407943B2
(en)
|
2001-08-01 |
2008-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein B expression
|
US7227014B2
(en)
|
2001-08-07 |
2007-06-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein (a) expression
|
NZ573831A
(en)
|
2001-09-18 |
2010-07-30 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of tumor, particularly breast tumor - TAT193
|
US6750019B2
(en)
|
2001-10-09 |
2004-06-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
ATE516364T1
(de)
|
2001-10-09 |
2011-07-15 |
Isis Pharmaceuticals Inc |
Antisense-modulation der expression des insulinähnlicher-wachstumsfaktor-bindungsprotei s 5
|
MX339524B
(es)
|
2001-10-11 |
2016-05-30 |
Wyeth Corp |
Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
|
EP2325193A3
(en)
|
2001-11-02 |
2012-05-02 |
Insert Therapeutics, Inc. |
Methods and compositions for therapeutic use of RNA interference
|
US6965025B2
(en)
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
CA2471431A1
(en)
|
2002-01-02 |
2003-07-17 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
WO2003078576A2
(en)
*
|
2002-03-12 |
2003-09-25 |
Nitto Denko Corporation |
Vector for transfection of eukaryotic cells
|
US20030180712A1
(en)
|
2002-03-20 |
2003-09-25 |
Biostratum Ab |
Inhibition of the beta3 subunit of L-type Ca2+ channels
|
NZ535925A
(en)
|
2002-04-16 |
2008-06-30 |
Genentech Inc |
An isolated antibody that binds to a particular polypeptide
|
AU2002307776A1
(en)
*
|
2002-04-16 |
2003-10-27 |
Kamada Ltd. |
Ultrapure transferrin for pharmaceutical compositions
|
US7199107B2
(en)
|
2002-05-23 |
2007-04-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of kinesin-like 1 expression
|
US7074893B2
(en)
*
|
2002-06-03 |
2006-07-11 |
Regents Of The University Of Michigan |
Methods and compositions for the treatment of diseases associated with signal transduction aberrations
|
GB0215534D0
(en)
*
|
2002-07-04 |
2002-08-14 |
Ecole Polytech |
Selective photochemotherapy using oligonucleotide targeting agents
|
US7375093B2
(en)
|
2002-07-05 |
2008-05-20 |
Intrexon Corporation |
Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
|
US7785608B2
(en)
|
2002-08-30 |
2010-08-31 |
Wyeth Holdings Corporation |
Immunogenic compositions for the prevention and treatment of meningococcal disease
|
BR0314236A
(pt)
|
2002-09-13 |
2005-08-09 |
Replicor Inc |
Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos
|
WO2004031350A2
(en)
|
2002-09-26 |
2004-04-15 |
Amgen, Inc. |
Modulation of forkhead box o1a expression
|
WO2004044136A2
(en)
|
2002-11-05 |
2004-05-27 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2’-modified nucleosides for use in gene modulation
|
AU2003287505A1
(en)
|
2002-11-05 |
2004-06-03 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
EP2336318B1
(en)
|
2002-11-13 |
2013-04-24 |
Genzyme Corporation |
Antisense modulation of apolipoprotein b expression
|
ES2417879T3
(es)
|
2002-11-13 |
2013-08-09 |
Genzyme Corporation |
Modulación antisentido de la expresión de la apolipoproteína B
|
US7144999B2
(en)
|
2002-11-23 |
2006-12-05 |
Isis Pharmaceuticals, Inc. |
Modulation of hypoxia-inducible factor 1 alpha expression
|
US7465708B2
(en)
|
2002-11-25 |
2008-12-16 |
Mixson A James |
Branched cationic copolymers and methods for antimicrobial use
|
US7304161B2
(en)
|
2003-02-10 |
2007-12-04 |
Intrexon Corporation |
Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex
|
ES2400033T3
(es)
|
2003-02-11 |
2013-04-05 |
Antisense Therapeutics Ltd |
Modulación de la expresión del receptor del factor de crecimiento I similar a la insulina
|
US7456315B2
(en)
|
2003-02-28 |
2008-11-25 |
Intrexon Corporation |
Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
|
US7803781B2
(en)
|
2003-02-28 |
2010-09-28 |
Isis Pharmaceuticals, Inc. |
Modulation of growth hormone receptor expression and insulin-like growth factor expression
|
US20040185559A1
(en)
|
2003-03-21 |
2004-09-23 |
Isis Pharmaceuticals Inc. |
Modulation of diacylglycerol acyltransferase 1 expression
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
WO2004093788A2
(en)
*
|
2003-04-17 |
2004-11-04 |
The Trustees Of Columbia University In The City Ofnew York |
Desmoglein 4 is a novel gene involved in hair growth
|
US7399853B2
(en)
|
2003-04-28 |
2008-07-15 |
Isis Pharmaceuticals |
Modulation of glucagon receptor expression
|
CN1984921B
(zh)
|
2003-06-03 |
2010-06-16 |
Isis药物公司 |
存活蛋白表达的调节
|
ATE478963T1
(de)
|
2003-07-03 |
2010-09-15 |
Univ New Jersey Med |
Gene als diagnostische werkzeuge für autismus
|
WO2005013901A2
(en)
|
2003-07-31 |
2005-02-17 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding rnas
|
US7825235B2
(en)
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
TW200519202A
(en)
|
2003-09-18 |
2005-06-16 |
Lilly Co Eli |
Modulation of eIF4E expression
|
CN1882602B
(zh)
|
2003-10-10 |
2011-02-09 |
阿尔卡米亚肿瘤股份有限公司 |
在疾病治疗中乙酰透明质酸合成的调节和降解
|
US8507277B2
(en)
|
2003-10-24 |
2013-08-13 |
Gencia Corporation |
Nonviral vectors for delivering polynucleotides
|
CA2543257C
(en)
|
2003-10-24 |
2013-12-31 |
Gencia Corporation |
Methods and compositions for delivering polynucleotides
|
US8133733B2
(en)
|
2003-10-24 |
2012-03-13 |
Gencia Corporation |
Nonviral vectors for delivering polynucleotides to target tissues
|
US8062891B2
(en)
|
2003-10-24 |
2011-11-22 |
Gencia Corporation |
Nonviral vectors for delivering polynucleotides to plants
|
US20090123468A1
(en)
|
2003-10-24 |
2009-05-14 |
Gencia Corporation |
Transducible polypeptides for modifying metabolism
|
US20050191653A1
(en)
|
2003-11-03 |
2005-09-01 |
Freier Susan M. |
Modulation of SGLT2 expression
|
DK2161283T3
(da)
|
2003-11-17 |
2014-09-01 |
Genentech Inc |
SAMMENSÆTNINGER OMFATTENDE ANTISTOFFER MOD CD79b, SOM ER KONJUGERET TIL ET VÆKSTINHIBERENDE MIDDEL ELLER ET CYTOTOKSISK MIDDEL, OG FREMGANGSMÅDER TIL BEHANDLING AF TUMOR AF HÆMATOPOIETISK OPRINDELSE
|
WO2005071080A2
(en)
|
2004-01-20 |
2005-08-04 |
Isis Pharmaceuticals, Inc. |
Modulation of glucocorticoid receptor expression
|
US7468431B2
(en)
|
2004-01-22 |
2008-12-23 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP2 expression
|
US8569474B2
(en)
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
EP1730309B1
(en)
|
2004-03-15 |
2016-05-04 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for optimizing cleavage of rna by rnase h
|
DE102004013637A1
(de)
|
2004-03-19 |
2005-10-13 |
Capsulution Nanoscience Ag |
Verfahren zur Herstellung von CS-Partikeln und Mikrokapseln unter Verwendung poröser Template sowie CS-Partikel und Mikrokapseln
|
WO2005097207A2
(en)
*
|
2004-03-26 |
2005-10-20 |
Curis, Inc. |
Rna interference modulators of hedgehog signaling and uses thereof
|
US20050244869A1
(en)
|
2004-04-05 |
2005-11-03 |
Brown-Driver Vickie L |
Modulation of transthyretin expression
|
CA2605574A1
(en)
|
2004-04-20 |
2005-11-03 |
Galapagos N.V. |
Methods, compositions and compound assays for inhibiting amyloid-beta protein production
|
EP2259063B1
(en)
|
2004-04-27 |
2012-05-23 |
Galapagos N.V. |
Compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts
|
US7935510B2
(en)
|
2004-04-30 |
2011-05-03 |
Intrexon Corporation |
Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
US20090048192A1
(en)
*
|
2004-06-03 |
2009-02-19 |
Isis Pharmaceuticals, Inc. |
Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
|
EP1773997B1
(en)
|
2004-06-14 |
2011-11-23 |
Galapagos N.V. |
Methods for identification, and compounds useful for the treatment of degenerative & inflammatory diseases
|
TW200613554A
(en)
|
2004-06-17 |
2006-05-01 |
Wyeth Corp |
Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
|
ES2427046T3
(es)
|
2004-06-21 |
2013-10-28 |
Galapagos N.V. |
Métodos y medios para el tratamiento de la osteoartritis
|
US7884086B2
(en)
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
ATE514776T1
(de)
*
|
2004-10-05 |
2011-07-15 |
California Inst Of Techn |
Aptamer-regulierte nukleinsäuren und verwendungen davon
|
US8673268B2
(en)
|
2004-10-15 |
2014-03-18 |
Galapagos N.V. |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
|
US7485468B2
(en)
|
2004-10-15 |
2009-02-03 |
Galapagos Bv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
|
US9034650B2
(en)
|
2005-02-02 |
2015-05-19 |
Intrexon Corporation |
Site-specific serine recombinases and methods of their use
|
CA2596506C
(en)
|
2005-02-09 |
2021-04-06 |
Avi Biopharma, Inc. |
Antisense composition and method for treating muscle atrophy
|
ZA200707490B
(en)
|
2005-03-10 |
2008-12-31 |
Genentech Inc |
Methods and compositions for modulatiing vascular integrity
|
DK1866414T3
(da)
|
2005-03-31 |
2012-04-23 |
Calando Pharmaceuticals Inc |
Inhibitorer af ribonukleotidreduktase-underenhed 2 og anvendelser deraf.
|
WO2007005898A2
(en)
|
2005-07-05 |
2007-01-11 |
Cornell Research Foundation, Inc. |
Blocking leukocyte emigration and inflammation by interfering with cd99l2
|
WO2007019245A2
(en)
|
2005-08-03 |
2007-02-15 |
Board Of Control Of Michigan Technological University |
Methods for enhancing expression of secondary cell wall cellulose synthases in plants
|
US7807652B2
(en)
|
2005-11-21 |
2010-10-05 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP2 expression
|
JP5425474B2
(ja)
|
2006-01-26 |
2014-02-26 |
アイシス ファーマシューティカルズ, インコーポレーテッド |
ハンチンチン対する、組成物及びその使用
|
EP2007428A2
(en)
|
2006-04-05 |
2008-12-31 |
Genentech, Inc. |
Method for using boc/cdo to modulate hedgehog signaling
|
AU2007245599B2
(en)
|
2006-05-03 |
2012-05-10 |
Baltic Technology Development, Ltd. |
Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease
|
US8198253B2
(en)
|
2006-07-19 |
2012-06-12 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to HBXIP
|
SG173414A1
(en)
|
2006-07-28 |
2011-08-29 |
Sanofi Aventis Fr |
Composition and method for treatment of tumors
|
WO2008058291A2
(en)
|
2006-11-09 |
2008-05-15 |
California Institute Of Technology |
Modular aptamer-regulated ribozymes
|
AU2007333225B2
(en)
*
|
2006-12-08 |
2014-06-12 |
Massachusetts Institute Of Technology |
Delivery of nanoparticles and/or agents to cells
|
AR064642A1
(es)
|
2006-12-22 |
2009-04-15 |
Wyeth Corp |
Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
|
US8048998B2
(en)
*
|
2007-01-19 |
2011-11-01 |
Exiqon A/S |
Mediated cellular delivery of LNA oligonucleotides
|
EP2641971A1
(en)
|
2007-01-29 |
2013-09-25 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating protein expression
|
EP2436781B1
(en)
|
2007-02-22 |
2015-10-07 |
Genentech, Inc. |
Methods for detecting inflammatory bowel disease
|
WO2008122434A1
(en)
*
|
2007-04-05 |
2008-10-16 |
Symbiotec Gesellschaft Zur Forschung Und Entwicklung Auf Dem Gebiet Der Biotechnologie Mbh |
Bis-met histones
|
CN101848887A
(zh)
|
2007-05-29 |
2010-09-29 |
英特拉克森公司 |
通过蜕皮素受体复合物调节外源性基因表达的手性二酰基肼配体
|
MX2009013766A
(es)
|
2007-06-20 |
2010-02-01 |
Galapagos Nv |
Objetivos moleculares y compuestos, y metodos para identificar los mismos, utiles en el tratamiento de enfermedades degenerativas de los huesos y las articulaciones.
|
WO2009011855A2
(en)
*
|
2007-07-16 |
2009-01-22 |
California Institute Of Technology |
Selection of nucleic acid-based sensor domains within nucleic acid switch platform
|
JP2010536373A
(ja)
|
2007-08-23 |
2010-12-02 |
イントレキソン コーポレーション |
疾患を診断するための方法および組成物
|
US8367815B2
(en)
*
|
2007-08-28 |
2013-02-05 |
California Institute Of Technology |
Modular polynucleotides for ligand-controlled regulatory systems
|
US20120165387A1
(en)
|
2007-08-28 |
2012-06-28 |
Smolke Christina D |
General composition framework for ligand-controlled RNA regulatory systems
|
US8865667B2
(en)
*
|
2007-09-12 |
2014-10-21 |
California Institute Of Technology |
Higher-order cellular information processing devices
|
WO2009039001A1
(en)
*
|
2007-09-17 |
2009-03-26 |
Rohm And Haas Company |
Compositions and methods for the modification of physiological responses in plants
|
DK3156414T3
(da)
|
2007-09-26 |
2020-03-09 |
Intrexon Corp |
Syntetisk 5'utrs ekspressionsvektorer og fremgangsmåder til øgning af transgen ekspression
|
KR101666228B1
(ko)
|
2007-09-28 |
2016-10-13 |
인트렉손 코포레이션 |
생물치료학적 분자를 발현시키기 위한 치료학적 유전자-스위치 작제물 및 생물반응기, 및 이의 용도
|
MX2010003465A
(es)
|
2007-10-02 |
2010-07-05 |
Amgen Inc |
Incremento de eritropoyetina utilizando acidos nucleicos que hibridan para micro-arn y precursores de los mismos.
|
US7973019B1
(en)
|
2007-10-03 |
2011-07-05 |
Alcon Research, Ltd. |
Transferrin/transferrin receptor-mediated siRNA delivery
|
MX2010003720A
(es)
|
2007-10-08 |
2010-10-20 |
Intrexon Corp |
Celulas dendriticas creadas por ingenieria genetica y usos para el tratamiento de cancer.
|
EP2212425A2
(de)
|
2007-11-22 |
2010-08-04 |
Biontex Laboratories Gmbh |
Verbesserung von transfektionsergebnissen nicht-viraler genliefersysteme durch beeinflussung des angeborenen immunsystems
|
DE102008023913A1
(de)
|
2008-05-16 |
2009-11-19 |
Biontex Laboratories Gmbh |
Verbesserung von Transfektionsergebnissen nicht-viraler Genliefersysteme durch Beeinflussung des angeborenen Immunsystems
|
DE102008016275A1
(de)
|
2008-03-28 |
2009-11-19 |
Biontex Laboratories Gmbh |
Verbesserung von Transfektionsergebnissen nicht-viraler Genliefersysteme durch Blockierung des angeborenen Immunsystems
|
DE102007056488A1
(de)
|
2007-11-22 |
2009-07-23 |
Biontex Laboratories Gmbh |
Steigerung von Transfektionseffizienzen nicht-viraler Genliefersysteme durch Blockierung des angeborenen Immunsystems
|
US9029524B2
(en)
*
|
2007-12-10 |
2015-05-12 |
California Institute Of Technology |
Signal activated RNA interference
|
JP2011516065A
(ja)
|
2008-04-04 |
2011-05-26 |
カランド ファーマシューティカルズ, インコーポレイテッド |
Epas1阻害剤の組成物および使用
|
US8093043B2
(en)
|
2008-06-04 |
2012-01-10 |
New York University |
β-TrCP1, β-TrCP2 and RSK1 or RSK2 inhibitors and methods for sensitizing target cells to apoptosis
|
US8815818B2
(en)
|
2008-07-18 |
2014-08-26 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell delivery of RNAI
|
DK2331141T3
(en)
|
2008-08-25 |
2016-04-04 |
Excaliard Pharmaceuticals Inc |
Antisense oligonucleotides WHO IS TARGETING connective tissue, AND USES THEREOF
|
EP2352828B1
(en)
|
2008-09-11 |
2015-02-25 |
Galapagos N.V. |
Method for identifying compounds useful for increasing the functional activity and cell surface expression of cf-associated mutant cystic fibrosis transmembrane conductance regulator
|
US10138485B2
(en)
|
2008-09-22 |
2018-11-27 |
Rxi Pharmaceuticals Corporation |
Neutral nanotransporters
|
CN102203122A
(zh)
|
2008-11-05 |
2011-09-28 |
惠氏有限责任公司 |
用于预防β-溶血链球菌(BHS)疾病的多组分免疫原性组合物
|
CN102307997B
(zh)
|
2008-12-04 |
2018-03-30 |
库尔纳公司 |
通过抑制针对沉默调节蛋白1的天然反义转录物来治疗沉默调节蛋白1(sirt1)相关的疾病
|
MX2011005910A
(es)
|
2008-12-04 |
2011-06-17 |
Opko Curna Llc |
Tratamiento de enfermedades relacionadas con eritropoyetina (epo) mediante inhibicion del transcrito antisentido natural a eritropoyetina.
|
KR101840618B1
(ko)
|
2008-12-04 |
2018-03-20 |
큐알엔에이, 인크. |
종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
|
US9493774B2
(en)
|
2009-01-05 |
2016-11-15 |
Rxi Pharmaceuticals Corporation |
Inhibition of PCSK9 through RNAi
|
US9745574B2
(en)
|
2009-02-04 |
2017-08-29 |
Rxi Pharmaceuticals Corporation |
RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
EP2216341A1
(en)
|
2009-02-10 |
2010-08-11 |
Novozymes Biopharma UK Limited |
Transferrin variants and conjugates
|
CN102387817B
(zh)
|
2009-02-12 |
2018-01-30 |
库尔纳公司 |
通过抑制针对脑衍生神经营养因子(bdnf)的天然反义转录物来治疗bdnf相关的疾病
|
WO2010093906A2
(en)
|
2009-02-12 |
2010-08-19 |
Curna, Inc. |
Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf
|
US8329882B2
(en)
|
2009-02-18 |
2012-12-11 |
California Institute Of Technology |
Genetic control of mammalian cells with synthetic RNA regulatory systems
|
EP2398479A2
(en)
|
2009-02-19 |
2011-12-28 |
Galapagos N.V. |
Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
|
WO2010094733A2
(en)
|
2009-02-19 |
2010-08-26 |
Biofocus Dpi B.V. |
Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
|
WO2010094732A1
(en)
|
2009-02-19 |
2010-08-26 |
Biofocus Dpi B.V. |
Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
|
US20110319317A1
(en)
|
2009-03-04 |
2011-12-29 |
Opko Curna, Llc |
Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt1
|
EP2408919B1
(en)
|
2009-03-16 |
2017-10-18 |
CuRNA, Inc. |
Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
|
CA2755404C
(en)
|
2009-03-17 |
2020-03-24 |
Joseph Collard |
Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
|
EP2414830A2
(en)
|
2009-03-31 |
2012-02-08 |
Robert Zimmermann |
Modulation of adipose triglyceride lipase for prevention and treatment of cachexia, loss of weight and muscle atrophy and methods of screening therefor
|
WO2010112569A1
(en)
|
2009-03-31 |
2010-10-07 |
Robert Zimmermann |
Modulation of adipose triglyceride lipase for prevention and treatment of cachexia, loss of weight and muscle atrophy and methods of screening therefor
|
EP2414829A1
(en)
|
2009-04-01 |
2012-02-08 |
Galapagos N.V. |
Methods and means for treatment of osteoarthritis
|
US9145555B2
(en)
|
2009-04-02 |
2015-09-29 |
California Institute Of Technology |
Integrated—ligand-responsive microRNAs
|
AU2010237046B2
(en)
|
2009-04-17 |
2015-06-04 |
New York University |
Peptides targeting TNF family receptors and antagonizing TNF action, compositions, methods and uses thereof
|
EP3524275A1
(en)
|
2009-04-22 |
2019-08-14 |
Massachusetts Institute Of Technology |
Innate immune supression enables repeated delivery of long rna molecules
|
NO2424987T3
(hu)
|
2009-05-01 |
2018-04-14 |
|
|
EP2427553A4
(en)
|
2009-05-06 |
2012-11-07 |
Opko Curna Llc |
TREATMENT OF LIPID TRANSPORT AND METABOLISM-RELATED DISEASES BY INHIBITING THE NATURAL ANTISENSE TRANSCRIPT AGAINST A LIPID TRANSPORT AND METABOLIC TREATMENT
|
CN102803492B
(zh)
|
2009-05-06 |
2016-06-29 |
库尔纳公司 |
通过抑制针对三重四脯氨酸(ttp)的天然反义转录物来治疗ttp相关疾病
|
DK2432881T3
(en)
|
2009-05-18 |
2018-02-26 |
Curna Inc |
TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR
|
US8895527B2
(en)
|
2009-05-22 |
2014-11-25 |
Curna, Inc. |
Treatment of transcription factor E3 (TFE3) and insulin receptor substrate 2(IRS2) related diseases by inhibition of natural antisense transcript to TFE3
|
WO2010138806A2
(en)
|
2009-05-28 |
2010-12-02 |
Curna, Inc. |
Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
|
KR101801404B1
(ko)
|
2009-06-16 |
2017-12-20 |
큐알엔에이, 인크. |
콜라겐 유전자에 대한 천연 안티센스 전사체의 억제에 의한 콜라겐 유전자 관련된 질환의 치료
|
US8951981B2
(en)
|
2009-06-16 |
2015-02-10 |
Curna, Inc. |
Treatment of paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1
|
KR101807323B1
(ko)
|
2009-06-24 |
2017-12-08 |
큐알엔에이, 인크. |
Tnfr2에 대한 천연 안티센스 전사체의 억제에 의한 종양 괴사 인자 수용체 2(tnfr2) 관련된 질환의 치료
|
CA2765815A1
(en)
|
2009-06-26 |
2010-12-29 |
Opko Curna, Llc |
Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
|
WO2011015573A1
(en)
|
2009-08-03 |
2011-02-10 |
Galapagos Nv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
|
WO2011015572A1
(en)
|
2009-08-03 |
2011-02-10 |
Galapagos Nv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
|
ES2585360T3
(es)
|
2009-08-05 |
2016-10-05 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con un gen de la insulina (INS) por inhibición de la transcripción antisentido natural en un gen de la insulina (INS)
|
JP5964232B2
(ja)
|
2009-08-25 |
2016-08-03 |
カッパーアールエヌエー,インコーポレイテッド |
‘iqモチーフ含有gtpアーゼ活性化タンパク質’(iqgap)に対する天然アンチセンス転写産物の阻害によるiqgap関連疾患の治療
|
EP2473522B1
(en)
|
2009-09-02 |
2016-08-17 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
EP2488210A4
(en)
|
2009-10-12 |
2014-04-30 |
Smith Holdings Llc |
METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION USING IN VITO OR IN VITRO-ADMINISTERED OLIGONUCLEOTIDE MEDICAMENTS
|
BR112012009409A2
(pt)
|
2009-10-22 |
2017-02-21 |
Genentech Inc |
método de identificação de uma substância inibidora, molécula antagonista, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar a molécula, composição, artigo de fabricação, método de inibição de uma atividade biológica, método de tratamento de uma condição patológica, método para detectar msp em uma amostra e método para detectar hepsina em uma amostra
|
WO2011056234A1
(en)
|
2009-11-06 |
2011-05-12 |
Fibrogen, Inc. |
Treatment for radiation-induced disorders
|
CN103755809B
(zh)
|
2009-11-30 |
2016-06-01 |
霍夫曼-拉罗奇有限公司 |
治疗和诊断表达slc34a2(tat211=seqid2)的肿瘤的抗体
|
EP2509953B1
(en)
|
2009-12-11 |
2016-03-30 |
Genecode AS |
Methods of facilitating neural cell survival using gdnf family ligand (gfl) mimetics or ret signaling pathway activators
|
CA2782366A1
(en)
|
2009-12-16 |
2011-07-14 |
Opko Curna, Llc |
Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
|
EP2515947B1
(en)
|
2009-12-23 |
2021-10-06 |
CuRNA, Inc. |
Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
|
CA2782373C
(en)
|
2009-12-23 |
2019-03-26 |
Opko Curna, Llc |
Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf
|
EP2519634B1
(en)
|
2009-12-29 |
2016-06-01 |
CuRNA, Inc. |
TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63
|
EP2519633B1
(en)
|
2009-12-29 |
2017-10-25 |
CuRNA, Inc. |
Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
|
JP5886757B2
(ja)
|
2010-01-04 |
2016-03-16 |
カッパーアールエヌエー,インコーポレイテッド |
インターフェロン調節因子8(irf8)に対する天然アンチセンス転写物の阻害によるインターフェロン調節因子8(irf8)関連疾患の治療
|
US8912157B2
(en)
|
2010-01-06 |
2014-12-16 |
Curna, Inc. |
Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
|
US9200277B2
(en)
|
2010-01-11 |
2015-12-01 |
Curna, Inc. |
Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG
|
WO2011090971A2
(en)
|
2010-01-19 |
2011-07-28 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin as a treatment for male reproductive disorders
|
DK2529015T3
(en)
|
2010-01-25 |
2018-02-26 |
Curna Inc |
TREATMENT OF RNASE H1-RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO RNASE H1
|
JP5976548B2
(ja)
|
2010-02-22 |
2016-08-23 |
カッパーアールエヌエー,インコーポレイテッド |
Pycr1に対する天然アンチセンス転写物の阻害によるピロリン−5−カルボン酸レダクターゼ1(pycr1)関連疾患の治療
|
TW201437228A
(zh)
|
2010-02-23 |
2014-10-01 |
Genentech Inc |
用於診斷及治療腫瘤之組合物及方法
|
AU2011232435B2
(en)
|
2010-03-23 |
2016-01-28 |
Intrexon Corporation |
Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
|
EP2550000A4
(en)
|
2010-03-24 |
2014-03-26 |
Advirna Inc |
RNAI COMPOUNDS OF REDUCED SIZE ADMINISTERING
|
KR101900962B1
(ko)
|
2010-04-09 |
2018-09-20 |
큐알엔에이, 인크. |
섬유아세포 성장 인자 21 (fgf21)에 대한 자연 안티센스 전사체의 저해에 의한 섬유아세포 성장 인자 21 (fgf21) 관련된 질환의 치료
|
BR112012027547B1
(pt)
|
2010-04-29 |
2022-06-14 |
Ionis Pharmaceuticals, Inc |
Oligonucleotídeo modificado de fita simples, composição, e seus usos para tratar amiloidose transtirretina, reduzir os seus sintomas e para reduzir a expressão de mrna ou de proteína de transtirretina
|
SG185027A1
(en)
|
2010-05-03 |
2012-11-29 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of tumor
|
KR101936011B1
(ko)
|
2010-05-03 |
2019-01-07 |
큐알엔에이, 인크. |
시르투인 (sirt)에 대한 자연 안티센스 전사체의 저해에 의한 시르투인 (sirt) 관련된 질환의 치료
|
JP5866106B2
(ja)
|
2010-05-12 |
2016-02-17 |
コロンビア ユニヴァーシティ |
インスリンを産生し分泌する腸内分泌細胞の製造方法
|
TWI531370B
(zh)
|
2010-05-14 |
2016-05-01 |
可娜公司 |
藉由抑制par4天然反股轉錄本治療par4相關疾病
|
WO2011150005A2
(en)
|
2010-05-26 |
2011-12-01 |
Opko Curna Llc |
Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
|
JP5998131B2
(ja)
|
2010-07-14 |
2016-09-28 |
カッパーアールエヌエー,インコーポレイテッド |
Discslargehomolog(dlg)dlg1への天然アンチセンス転写物の阻害によるdlg関連疾患の治療
|
CN103189071A
(zh)
|
2010-08-23 |
2013-07-03 |
惠氏有限责任公司 |
脑膜炎萘瑟氏菌rLP2086抗原的稳定制剂
|
WO2012032489A1
(en)
|
2010-09-10 |
2012-03-15 |
Wyeth Llc |
Non-lipidated variants of neisseria meningitidis orf2086 antigens
|
EP2625197B1
(en)
|
2010-10-05 |
2016-06-29 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
KR101886457B1
(ko)
|
2010-10-06 |
2018-08-07 |
큐알엔에이, 인크. |
시알리다아제 4 (neu4)에 대한 자연 안티센스 전사체의 저해에 의한 neu4 관련된 질환의 치료
|
JP6049623B2
(ja)
|
2010-10-22 |
2016-12-21 |
カッパーアールエヌエー,インコーポレイテッド |
α‐L‐イズロニダーゼ(IDUA)への天然アンチセンス転写物の阻害によるIDUA関連疾患の治療
|
CN103201387B
(zh)
|
2010-10-27 |
2018-02-02 |
库尔纳公司 |
通过抑制干扰素相关发育调节因子1(ifrd1)的天然反义转录物而治疗ifrd1相关疾病
|
WO2012061811A2
(en)
|
2010-11-05 |
2012-05-10 |
Fibrogen, Inc. |
Treatment method for lung remodeling diseases
|
CA2818824A1
(en)
|
2010-11-23 |
2012-05-31 |
Joseph Collard |
Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
|
AU2012212110A1
(en)
|
2011-02-02 |
2013-08-01 |
Excaliard Pharmaceuticals, Inc. |
Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (CTGF)
|
WO2012109495A1
(en)
|
2011-02-09 |
2012-08-16 |
Metabolic Solutions Development Company, Llc |
Cellular targets of thiazolidinediones
|
SG192856A1
(en)
|
2011-03-04 |
2013-09-30 |
Intrexon Corp |
Vectors conditionally expressing protein
|
JP5951752B2
(ja)
|
2011-04-13 |
2016-07-13 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
Ptp1b発現のアンチセンス調節
|
RU2620980C2
(ru)
|
2011-06-09 |
2017-05-30 |
Курна, Инк. |
Лечение заболеваний, связанных с фратаксином (fxn), путем ингибирования природного антисмыслового транскрипта fxn
|
EP2721156B1
(en)
|
2011-06-16 |
2016-12-21 |
Ionis Pharmaceuticals, Inc. |
Antisense modulation of fibroblast growth factor receptor 4 expression
|
FR2979919B1
(fr)
|
2011-09-12 |
2015-12-11 |
Centre Nat Rech Scient |
Genomes lentiviraux chimeriques non-integratifs comme vaccins innovants contre vih-1
|
BR112014006587B1
(pt)
|
2011-09-20 |
2021-07-27 |
Ionis Pharmaceuticals, Inc |
Composto compreendendo oligonucleotídeo que modula a expressão de gcgr, composição, bem como seu uso no tratamento ou prevenção de diabetes
|
BR112014006535A2
(pt)
|
2011-09-20 |
2017-03-28 |
Univ North Carolina Chapel Hill |
regulação dos canais de sódio através das proteínas plunc
|
FR2980801B1
(fr)
|
2011-09-29 |
2016-02-05 |
Centre Nat Rech Scient |
Utilisation de "polyketide synthases" de type iii (pks iii) recombinantes d'algues brunes marines
|
US20130085139A1
(en)
|
2011-10-04 |
2013-04-04 |
Royal Holloway And Bedford New College |
Oligomers
|
US8901098B2
(en)
|
2011-10-25 |
2014-12-02 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of GCCR expression
|
AU2013229063B2
(en)
|
2012-03-09 |
2016-10-06 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
WO2013138374A2
(en)
|
2012-03-15 |
2013-09-19 |
Curna, Inc. |
Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
|
WO2014041179A1
(en)
|
2012-09-17 |
2014-03-20 |
Chemedest Ltd. |
Treatment of peripheral neuropathy using gfr(alpha)3 type receptor agonists
|
CN103772503B
(zh)
|
2012-10-22 |
2017-05-10 |
泉盛生物科技股份有限公司 |
介白素‑6抗体及其用途
|
EP2920304B1
(en)
|
2012-11-15 |
2019-03-06 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide conjugates
|
CA2903716C
(en)
|
2013-03-08 |
2019-04-09 |
Pfizer Inc. |
Immunogenic fusion polypeptides
|
WO2014139884A2
(en)
|
2013-03-14 |
2014-09-18 |
Galapagos Nv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of fibrosis
|
JP6437467B2
(ja)
|
2013-03-14 |
2018-12-19 |
ガラパゴス・ナムローゼ・フェンノートシャップGalapagos N.V. |
線維化疾患治療において有用な分子標的及び化合物、並びにこれらの同定方法
|
WO2014139885A2
(en)
|
2013-03-14 |
2014-09-18 |
Galapagos Nv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of diseases associated with epithelial mesenchymal transition
|
WO2014152497A2
(en)
|
2013-03-15 |
2014-09-25 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin as a treatment for cognitive disorders
|
ES2862125T3
(es)
|
2013-06-13 |
2021-10-07 |
Antisense Therapeutics Ltd |
Terapia combinada para acromegalia
|
KR20210088009A
(ko)
|
2013-09-05 |
2021-07-13 |
사렙타 쎄러퓨틱스, 인코퍼레이티드 |
산성 알파-글루코시다제 내 안티센스-유도된 엑손2 포함
|
KR102199096B1
(ko)
|
2013-09-08 |
2021-01-06 |
화이자 인코포레이티드 |
나이세리아 메닌지티디스 조성물 및 그의 방법
|
US10036020B2
(en)
|
2013-09-19 |
2018-07-31 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Compositions and methods for inhibiting JC virus (JCV)
|
WO2015116902A1
(en)
|
2014-01-31 |
2015-08-06 |
Genentech, Inc. |
G-protein coupled receptors in hedgehog signaling
|
AU2015214264B2
(en)
|
2014-02-04 |
2018-12-20 |
Curis, Inc. |
Mutant Smoothened and methods of using the same
|
KR101605421B1
(ko)
|
2014-03-05 |
2016-03-23 |
국립암센터 |
B 세포 림프종 세포를 특이적으로 인지하는 단일클론항체 및 이의 용도
|
WO2015171918A2
(en)
|
2014-05-07 |
2015-11-12 |
Louisiana State University And Agricultural And Mechanical College |
Compositions and uses for treatment thereof
|
GB2526867A
(en)
|
2014-06-05 |
2015-12-09 |
Oxitec Ltd |
Gene expression system
|
WO2015200901A1
(en)
|
2014-06-26 |
2015-12-30 |
The Trustees Of Columbia University In The City Of New York |
Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells
|
WO2016011203A1
(en)
|
2014-07-15 |
2016-01-21 |
Life Technologies Corporation |
Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
|
WO2016033424A1
(en)
|
2014-08-29 |
2016-03-03 |
Genzyme Corporation |
Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
|
WO2016081728A1
(en)
|
2014-11-19 |
2016-05-26 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin as a treatment for frailty associated with aging
|
KR102554850B1
(ko)
|
2015-02-06 |
2023-07-13 |
더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 |
최적화된 인간 응고 인자 viii 유전자 발현 카세트 및 그의 용도
|
RU2723045C2
(ru)
|
2015-02-19 |
2020-06-08 |
Пфайзер Инк. |
Композиции neisseria meningitidis и способы их получения
|
MA41795A
(fr)
|
2015-03-18 |
2018-01-23 |
Sarepta Therapeutics Inc |
Exclusion d'un exon induite par des composés antisens dans la myostatine
|
MA50829A
(fr)
|
2015-06-01 |
2018-04-11 |
Sarepta Therapeutics Inc |
Exclusion d'exon induite pat technologie antisens dans le collagène de type vii
|
WO2017058881A1
(en)
|
2015-09-28 |
2017-04-06 |
The Trustees Of Columbia University In The City Of New York |
Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
|
MA45819A
(fr)
|
2015-10-09 |
2018-08-15 |
Sarepta Therapeutics Inc |
Compositions et méthodes pour traiter la dystrophie musculaire de duchenne et troubles associés
|
CA3001590A1
(en)
|
2015-10-10 |
2017-04-13 |
Intrexon Corporation |
Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
|
WO2017075670A1
(en)
|
2015-11-05 |
2017-05-11 |
Children's Hospital Los Angeles |
"mobilizing leukemia cells"
|
CN106699889A
(zh)
|
2015-11-18 |
2017-05-24 |
礼进生物医药科技(上海)有限公司 |
抗pd-1抗体及其治疗用途
|
EP3411396A1
(en)
|
2016-02-04 |
2018-12-12 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
WO2017147128A1
(en)
|
2016-02-22 |
2017-08-31 |
The University Of North Carolina At Chapel Hill |
Peptide inhibitors of calcium channels
|
KR102522059B1
(ko)
|
2016-04-18 |
2023-04-14 |
사렙타 쎄러퓨틱스 인코퍼레이티드 |
안티센스 올리고머, 및 산성 알파-글루코시다제 유전자와 연관된 질환을 치료하기 위한 이의 사용 방법
|
US11827876B2
(en)
|
2016-08-12 |
2023-11-28 |
Oxitec Ltd. |
Self-limiting, sex-specific gene and methods of using
|
EA201990864A1
(ru)
|
2016-11-09 |
2019-11-29 |
|
Конструкции для экспрессии фратаксина
|
US10183070B2
(en)
|
2017-01-31 |
2019-01-22 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
US10994025B2
(en)
|
2017-05-12 |
2021-05-04 |
Massachusetts Institute Of Technology |
Argonaute protein-double stranded RNA complexes and uses related thereto
|
US11555189B2
(en)
|
2017-10-18 |
2023-01-17 |
Sarepta Therapeutics, Inc. |
Antisense oligomer compounds
|
KR101915949B1
(ko)
|
2018-01-09 |
2018-11-07 |
주식회사 쎌바이오텍 |
유전자 발현 카세트 및 그를 포함하는 발현벡터
|
AR117409A1
(es)
|
2018-03-29 |
2021-08-04 |
Oxitec Ltd |
Noctuidas autolimitantes
|
EP3772928A4
(en)
|
2018-04-06 |
2021-12-29 |
Children's Medical Center Corporation |
Compositions and methods for somatic cell reprogramming and modulating imprinting
|
SG11202101169PA
(en)
|
2018-08-10 |
2021-03-30 |
Eutilex Co Ltd |
Chimeric antigen receptor that binds hla-dr and car-t cell
|
MX2021001708A
(es)
|
2018-08-14 |
2021-04-19 |
Oxitec Ltd |
Autoseleccion de artropodos machos esteriles.
|
AU2019406453A1
(en)
|
2018-12-21 |
2021-07-22 |
Ose Immunotherapeutics |
Bifunctional molecule directed against human PD-1
|
WO2020127367A1
(en)
|
2018-12-21 |
2020-06-25 |
Ose Immunotherapeutics |
Humanized anti-human-pd-1 antibody
|
WO2020127373A1
(en)
|
2018-12-21 |
2020-06-25 |
Ose Immunotherapeutics |
Bifunctional anti-pd-1/sirpa molecule
|
KR20210108978A
(ko)
|
2018-12-21 |
2021-09-03 |
오제 이뮈노테라프틱스 |
이작용성 항-pd-1/il-7 분자
|
WO2020165374A1
(en)
|
2019-02-14 |
2020-08-20 |
Ose Immunotherapeutics |
Bifunctional molecule comprising il-15ra
|
AU2020236937B2
(en)
|
2019-03-08 |
2023-06-15 |
Obsidian Therapeutics, Inc. |
CD40L compositions and methods for tunable regulation
|
EP3835421A1
(en)
|
2019-12-11 |
2021-06-16 |
Consejo Superior de Investigaciones Científicas (CSIC) |
Vectors for tissue specific transcriptomics
|
US20230056856A1
(en)
|
2020-01-08 |
2023-02-23 |
Obsidian Therapeutics, Inc. |
Compositions and methods for tunable regulation of transcription
|
EP4144857A4
(en)
|
2020-03-06 |
2024-02-28 |
Mingceler Biotechnology Co Ltd |
PROCESS FOR PREPARING AN ANIMAL
|
EP4240408A1
(en)
|
2020-11-05 |
2023-09-13 |
Neoimmunetech, Inc. |
Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine
|
EP4019539A1
(en)
|
2020-12-22 |
2022-06-29 |
Consejo Superior de Investigaciones Científicas (CSIC) |
Recombinant bacterium and uses thereof
|
WO2022226291A1
(en)
|
2021-04-22 |
2022-10-27 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating cancer
|